AbbVie (ABBV) Issues Positive Update on ABT-493 and ABT-530 w/ RBV in HCV GT1 (ENTA)

April 15, 2016 6:38 AM EDT Send to a Friend
AbbVie (NYSE: ABBV) announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login